Comparison of the AUDIT test results and laboratory control of phosphatidylethanol in blood in order to determine alcohol consumption pattern in patients with alcoholic liver cirrhosis
Suggested citation:
Ikonnikova KA, Eroshchenko NN, Klimenko TV, et al. [Comparison of the AUDIT test results and laboratory control of phosphatidylethanol in blood in order to determine alcohol consumption pattern in patients with alcoholic liver cirrhosis]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2022;(1):73-80. Russian
The aim of this cohort observational study was to compare the pattern of alcohol consumption according to the results of the AUDIT (Alcohol Use Disorders Inventory Test) with laboratory monitoring of biomarker of alcohol consumption phosphatidylethanol (Peth 16-0:18-1) in men over 18 years of age (n=112) with a history of alcohol-related liver disease. According to the results of AUDIT (8 or more points) excessive alcohol consumption was found in 52 (46.4%) patients, while phosphatidylethanol in the blood was detected in 74 people (66%). In group with 0–7 AUDIT score phosphatidylethanol was found in blood of 36.6% patients, in the group with 16-19 points – in 100%. In the group with 20 or more AUDIT score, the marker was found in 5 out of 8 patients (62.5%) with concentration range 61.2-251.1 ng/ml, which suggests that this group included patients with different alcohol drinking pattern. The situation is similar in other groups. There was no relationship between phosphatidiethanol levels in blood and AUDIT results. Data from the two tests indicate that patients had difficulty completing the AUDIT questionnaire, therefore it is advisable to include laboratory diagnostics of phosphatidylethanol in the examination of patients with suspected excessive alcohol consumption.
Keywords Alcohol Use Disorders Inventory Test (AUDIT); phosphatidylethanol; alcohol biomarkers
1. World Health Organization. Global status report on alcohol and health 2018. 450 p. 2. Parry CD, Patra J, Rehm J. Alcohol consumption and non-communicable diseases: epidemiology and policy implications. Addiction. 2011;106(10):1718–24. DOI: https://doi.org/10.1111/j.1360-0443.2011.03605.x 3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. Journal of Hepatology. 2018;69(1):154–81. DOI: https://doi.org/10.1016/j.jhep.2018.03.018 4. Ivashkin VT, Maevskaya MV, Pavlov ChS, et al. [Management of adult patients with alcoholic liver disease: clinical guidelines of the Russian Scientific Liver Society]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2017;27(6):20–40. (In Russ.) DOI: https://doi.org/10.22416/1382-4376-2017-27-6-20-40 5. Sepanlou SG, Safiri S, Bisignano C, Ikuta, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology. 2020;5(3):245–66. DOI: https://doi.org/10.1016/S2468-1253(19)30349-8 6. Gofman AG, Ponizovskii PA. [Comorbidity of mental desorders with alcohol addiction]. Voprosy narkologii. 2018;2:102–13. (In Russ.) 7. Lai HMX, Cleary M, Sitharthan T, Hunt GE. Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic review and meta-analysis. Drug and Alcohol Dependence. 2015;154:1–13. DOI: https://doi.org/10.1016/j.drugalcdep.2015.05.031 8. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol use disorders identification test. 2001. 37 р. 9. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption-II. Addiction. 1993;88(6):791–804. DOI: https://doi.org/10.1111/j.1360-0443.1993.tb02093.x 10. Lange S, Shield K, Monteiro M, Rehm J. Facilitating Screening and Brief Interventions in Primary Care: A Systematic Review and Meta‐Analysis of the AUDIT as an Indicator of Alcohol Use Disorders // Alcoholism: Clinical and Experimental Research. Blackwell Publishing Ltd. 2019;43(10):2028–37. DOI: https://doi.org/10.1111/acer.14171 11. Aradottir S, Asanovska G, Gjerss S, et al. Phosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol and Alcoholism. 2006;41(4):431–7. DOI: https://doi.org/10.1093/alcalc/agl027 12. Hartmann S, Aradottir S, Graf M, et al. Phosphatidylethanol as a sensitive and specific biomarkerс–comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin. Addiction Biology. 2007;12(1):81–4. DOI: https://doi.org/10.1111/j.1369-1600.2006.00040.x 13. Kummer N, Ingels AS, Wille SM, et al. Quantification of phosphatidylethanol 16:0/18:1, 18:1/18:1, and 16:0/16:0 in venous blood and venous and capillary dried blood spots from patients in alcohol withdrawal and control volunteers. Analytical and Bioanalytical Chemistry. 2016;408(3):825–38. DOI: https://doi.org/10.1007/s00216-015-9169-1 14. Gnann H, Weinmann W, Thierauf A. Formation of Phosphatidylethanol and Its Subsequent Elimination During an Extensive Drinking Experiment Over 5 Days. Alcoholism: Clinical and Experimental Research. 2012;36(9):1507–11. DOI: https://doi.org/10.1111/j.1530-0277.2012.01768.x 15. Dasgupta A. Alcohol and Its Biomarkers: Clinical Aspects and Laboratory Determination. Alcohol and Its Biomarkers: Clinical Aspects and Laboratory Determination. Elsevier Inc., 2015. 300 p. 16. Stewart SH, Koch DG, Willner IR, et al. Validation of Blood Phosphatidylethanol as an Alcohol Consumption Biomarker in Patients with Chronic Liver Disease. Alcoholism: Clinical and Experimental Research. Blackwell Publishing Ltd. 2014;38(6):1706–11. DOI: https://doi.org/10.1111/acer.12442 17. Andresen‐Streichert H, Beres Y, Weinmann W, et al. Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transplant International. Blackwell Publishing Ltd. 2017;30(6):611–20. DOI: https://doi.org/10.1111/tri.12949 18. Helander A, Böttcher M, Dahmen N, et al. Elimination Characteristics of the Alcohol Biomarker Phosphatidylethanol (PEth) in Blood during Alcohol Detoxification. Alcohol and Alcoholism. 2019;54(3):251–7. DOI: https://doi.org/10.1093/alcalc/agz027 19. Helander A, Hermansson U, Beck O. Dose–Response Characteristics of the Alcohol Biomarker Phosphatidylethanol (PEth) – A Study of Outpatients in Treatment for Reduced Drinking. Alcohol and Alcoholism. 2019;54(6):567–73. DOI: https://doi.org/10.1093/alcalc/agz064 20. Walther L, de Bejczy A, Löf E, et al. Phosphatidylethanol is Superior to Carbohydrate-Deficient Transferrin and γ -Glutamyltransferase as an Alcohol Marker and is a Reliable Estimate of Alcohol Consumption Level. Alcoholism: Clinical and Experimental Research. Blackwell Publishing Ltd. 2015;39(11):2200–8. DOI: https://doi.org/10.1111/acer.12883 21. Viel G, Boscolo-Berto R, Cecchetto G, et al. Phosphatidylethanol in Blood as a Marker of Chronic Alcohol Use: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2012;13(12):14788–812. DOI: https://doi.org/10.3390/ijms131114788 22. Simon TW. Providing context for phosphatidylethanol as a biomarker of alcohol consumption with a pharmacokinetic model. Regulatory Toxicology and Pharmacology. 2018;94:163–71. DOI: https://doi.org/10.1016/j.yrtph.2018.01.029 23. World Health Organization. International guide for monitoring alcohol consumption and related harm. WHO/MSD/MSB/00.4. 2000. 193 p. 24. Helander A, Zheng Y. Molecular Species of the Alcohol Biomarker Phosphatidylethanol in Human Blood Measured by LC-MS. Clinical Chemistry. 2009;55(7):1395–405. DOI: https://doi.org/10.1373/clinchem.2008.120923 25. Babor TF, Robaina K. The Alcohol Use Disorders Identification Test (AUDIT): A review of graded severity algorithms and national adaptations. The International Journal of Alcohol and Drug Research. 2016;5(2):17–24. DOI: https://doi.org/10.7895/ijadr.v5i2.222 26. Pavlov AI. [Alcoholic liver disease: diagnosis and management in general hospital]. Effektivnaya farmakoterapiya. 2013;41:30–7. (In Russ.)
DOI: http://dx.doi.org/10.47877/1560-957Х-2022-10109
Article Metrics
Metrics powered by PLOS ALM